Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas
Authors:
- Ulrich RoelckeURUlrich Roelcke
- Matthias T. WyssMWMatthias T. Wyss
- Martha NowosielskiMNMartha Nowosielski
- Roberta RudàRRRoberta Rudà
- Patrick RothPRPatrick Roth
- Silvia HoferSHSilvia Hofer
- Norbert GalldiksNGNorbert Galldiks
- Flavio CrippaFCFlavio Crippa
- Michael WellerMWMichael Weller
- Riccardo SoffiettiRiccardo Soffietti
Open Access
- 17 November 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (5) , 744-751
Abstract
Patients with WHO grade II glioma may respond to chemotherapy that is currently not standardized regarding timing and treatment duration. Metabolic changes during chemotherapy may precede structural tumor volume reductions. We therefore compared time courses of amino acid PET and MRI responses to temozolomide (TMZ) and assessed whether responses correlated with seizure control and progression-free survival (PFS). PET and MRI were performed before and during TMZ chemotherapy. Tumor volumes were calculated using regions-of-interest analysis. Amino acid uptake was also quantified as metabolically active tumor volume and tumor-to-cerebellum uptake ratio. One hundred twenty-five PET and 125 MRI scans from 33 patients were analyzed. Twenty-five patients showed metabolic responses that exhibited an exponential time course with a 25% reduction of the active volume on average after 2.3 months. MRI responses followed a linear course with a 25% reduction after 16.8 months. Reduction of metabolically active tumor volumes, but not reduction of PET uptake ratios or MRI tumor volumes, correlated with improved seizure control following chemotherapy (P = .012). Receiver-operating-characteristic curve analysis showed that a decrease of the active tumor volume of ≥80.5% predicts a PFS of ≥60 months (P = .018) and a decrease of ≥64.5% a PFS of ≥48 months (P = .037). Amino acid PET is superior to MRI for evaluating TMZ responses in WHO grade II glioma patients. The response delay between both imaging modalities favors amino acid PET for individually tailoring the duration of chemotherapy. Additional studies should investigate whether this personalized approach is appropriate with regard to outcome.Keywords
This publication has 26 references indexed in Scilit:
- Treatment-related myelodysplasia in patients with primary brain tumorsNeuro-Oncology, 2012
- Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatmentBrain, 2011
- Glutamate release by primary brain tumors induces epileptic activityNature Medicine, 2011
- Seizures and the Natural History of World Health Organization Grade II Gliomas: A ReviewNeurosurgery, 2011
- Update on molecular findings, management and outcome in low-grade gliomasNature Reviews Neurology, 2010
- Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task ForceEuropean Journal of Neurology, 2010
- Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomasNeuro-Oncology, 2010
- Spatial Heterogeneity of Low-Grade Gliomas at the Capillary Level: A PET Study on Tumor Blood Flow and Amino Acid UptakeJournal of Nuclear Medicine, 2007
- Dynamic history of low‐grade gliomas before and after temozolomide treatmentAnnals of Neurology, 2007
- PET Study of Methionine Accumulation in Glioma and Normal Brain TissueJournal of Computer Assisted Tomography, 1987